EASD 2019: Delegates updated on Novo Nordisk’s Oral Semaglutide PIONEER trial

shutterstock_182417234
This trial is investigating the long-term efficacy and safety of oral semaglutide, which is currently available on the market as Novo Nordisk’s subcutaneous injectable formulation, Ozempic.